Sagility Limited (NSE:SAGILITY)
India
· Delayed Price · Currency is INR | Market Cap | 193.20B |
| Revenue (ttm) | 67.37B |
| Net Income (ttm) | 8.50B |
| Shares Out | 4.68B |
| EPS (ttm) | 1.80 |
| PE Ratio | 22.89 |
| Forward PE | 17.62 |
| Dividend | 0.10 (0.24%) |
| Ex-Dividend Date | Nov 12, 2025 |
| Volume | 7,438,108 |
| Average Volume | 15,918,572 |
| Open | 41.50 |
| Previous Close | 41.27 |
| Day's Range | 41.43 - 41.90 |
| 52-Week Range | 35.83 - 57.89 |
| Beta | n/a |
| RSI | 49.15 |
| Earnings Date | May 14, 2026 |
About Sagility
Sagility Limited engages in the provision of business process management services to the healthcare and insurance industries in India, Jamaica, the Philippines, the United States, and Colombia. The company offers claims cost containment and management, member and provider engagement, enrolment, benefits plan building, payment integrity and billing, credentialing, clinical and case management, provider network operation services, analytics, front and back-office, administrative support provider, and data management services. It also provides uti... [Read more]
Financial Performance
In fiscal year 2025, Sagility's revenue was 55.70 billion, an increase of 17.17% compared to the previous year's 47.54 billion. Earnings were 5.39 billion, an increase of 136.18%.
Financial StatementsNews
Sagility Transcript: Investor Day 2026
Sagility is leveraging deep healthcare expertise and AI-driven transformation to expand managed services and Synchrony offerings, targeting both large and mid-market clients. AI is positioned as a growth accelerator, enabling cost reduction, operational efficiency, and new business models, while maintaining strong margins and client relationships.
Sagility Transcript: Q3 25/26
Q3 FY26 saw exceptional revenue and profit growth, driven by strong payer and provider segments and boosted by BroadPath's contribution to open enrollment. Guidance for FY26 revenue growth was raised to 22.5%, with margins holding steady despite ongoing margin pressures and regulatory changes.
Sagility Transcript: Q2 25/26
Q2 and H1 FY26 saw robust revenue and profit growth, with strong performance in both payer and provider segments. AI-driven transformation and new deal constructs are driving efficiency and client value, while guidance for FY26 revenue and margins has been raised. Seasonality will favor H2, and prudent capital management continues.
Sagility Transcript: Q1 25/26
Q1 FY 2026 saw 25.8% revenue growth and 26.5% adjusted EBITDA growth year-on-year, with strong performance across payer and provider segments. Guidance for FY 2026 is raised to 24%+ EBITDA margin and 20%+ growth with BroadPath, supported by robust client wins and ongoing digital transformation.
Sagility Transcript: Q4 24/25
Q4 and FY25 saw robust revenue and profit growth, driven by client expansion, technology-enabled services, and the BroadPath acquisition. Guidance remains for low-to-mid teens organic growth and 24%-25% EBITDA margin, with strong cash flows funding all obligations.
Sagility Transcript: Q3 24/25
Q3 FY25 delivered 15.3% year-on-year revenue growth and a 67% rise in adjusted EBITDA, driven by Open Enrollment seasonality and operational efficiencies. The BroadPath acquisition expands mid-market reach and is immediately EPS accretive.
Sagility Transcript: Q2 24/25
Q2 FY25 saw 21.1% YoY revenue growth and 25.5% EBITDA margin, driven by strong client demand and technology investments. The business remains focused on U.S. healthcare, expanding in mid-market segments, and maintaining robust cash flow and low leverage.